HIV Articles
Back
	Dolutegravir FDA CLINICAL REVIEW       Phase 3 Assessment of Dolutegravir (DTG) 50 mg Twice Daily (BID) in HIV-1-Infected Subjects With Raltegravir (RAL) and/or Elvitegravir (EVG) Resistance in VIKING-3: Week 24 Results of All 183 Subjects Enrolled http://www.natap.org/2013/IAS/IAS_21.htm   Download the PDF here   Download the PDF here   Download the PDF here             View Older Articles   Back to Top   www.natap.org